Poly Medicure Limited (BOM:531768)
India · Delayed Price · Currency is INR | Market Cap | 136.67B -46.7% |
| Revenue (ttm) | 18.75B +12.3% |
| Net Income | 3.22B -4.8% |
| EPS | 31.75 -6.9% |
| Shares Out | 101.36M |
| PE Ratio | 42.47 |
| Forward PE | 34.89 |
| Dividend | 3.50 (0.26%) |
| Ex-Dividend Date | Sep 18, 2025 |
| Volume | 13,896 |
| Open | 1,331.25 |
| Previous Close | 1,328.60 |
| Day's Range | 1,320.00 - 1,396.90 |
| 52-Week Range | 1,184.00 - 2,356.00 |
| Beta | 0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 25, 2026 |
About Poly Medicure
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous cat... [Read more]
Financial Performance
In fiscal year 2026, Poly Medicure's revenue was 18.75 billion, an increase of 12.30% compared to the previous year's 16.70 billion. Earnings were 3.22 billion, a decrease of -4.85%.
Financial StatementsNews
Poly Medicure cancels investor meeting scheduled for 27th May 2026
Poly Medicure has announced the cancellation of an investor meeting that was scheduled for 27th May 2026. The meeting, which was to be held at the company's plant in Faridabad,…
Poly Medicure Transcript: Q4 25/26
FY 2026 saw a strategic pivot to high-tech segments, 12.3% consolidated revenue growth, and strong margin performance despite raw material and logistics headwinds. FY 2027 guidance targets 23–25% consolidated EBITDA margin and 20%+ growth in key segments.
Poly Medicure Quarterly report: Q4 2026
Poly Medicure has published its Q4 2026 quarterly earnings report on May 25, 2026.
Poly Medicure Slides: Q4 2026
Poly Medicure has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 25, 2026.
Top losers in morning trade: gujarat state petronet at ₹268.35 down 7.13%, poly medicure at ₹1,520.00 falls 4.89%, polyplex corporation at ₹914.50 down 4.88%
The Indian stock market displayed a mixed sentiment today, with the SENSEX rising by 1.50% to 76,549.82 and the NIFTY 50 gaining 1.39% to reach 24,049.55. Despite the overall positive…
Poly Medicure Q4 Results: Net profit falls 27.8% YoY to Rs 66.3 crore, revenue rises 21.3%
Medical devices maker Poly Medicure reported a mixed set of Q4 FY26 earnings on May 25, 2026, as strong revenue growth was overshadowed by pressure on profitability and margins. Following…
Poly Medicure Slides: Investor presentation
Poly Medicure has posted slides in relation to its latest quarterly earnings report, which was published on March 7, 2026.
Poly Medicure Transcript: Q3 25/26
Q3 FY26 saw 16.4% YoY revenue growth, strong gross margins, and robust domestic and international expansion, driven by acquisitions and new product launches. Guidance for FY27 targets 20%+ consolidated revenue growth, with continued margin strength and significant CapEx for capacity expansion.
Poly Medicure Quarterly report: Q3 2026
Poly Medicure has published its Q3 2026 quarterly earnings report on February 6, 2026.
Poly Medicure Slides: Q3 2026
Poly Medicure has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 6, 2026.
Poly Medicure Transcript: Q2 25/26
Q2 and H1 FY26 saw steady revenue and margin growth, with strong domestic performance and recovering international markets. Two European acquisitions are expected to boost annual revenue, while guidance for FY26 is revised to 15%-16% growth and 25%-27% EBITDA margin.
Poly Medicure Quarterly report: Q2 2026
Poly Medicure has published its Q2 2026 quarterly earnings report on November 10, 2025.
Poly Medicure Slides: Q2 2026
Poly Medicure has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 10, 2025.
Poly Medicure Transcript: M&A Announcement
The acquisition secures a leading position in the orthopedic trauma and extremity market, with CTFE's strong product portfolio and direct sales presence in key geographies. The deal is valued at €31 million enterprise value, with significant growth and synergy potential, especially through portfolio expansion and leveraging global distribution.
Poly Medicure Press release: M&A Announcement
Poly Medicure issued a press release on September 25, 2025, disclosing material business information to investors.
Poly Medicure Slides: M&A Announcement
Poly Medicure has posted slides in relation to its latest quarterly earnings report, which was published on September 25, 2025.
Poly Medicure acquires Italy’s Citieffe for Rs 324 crore
Poly Medicure Ltd, one of India’s top medical device companies, has announced a major global expansion move. The company has signed a definitive agreement to acquire 100% stake in Medistream SA, which...
Poly Medicure Transcript: M&A Announcement
The acquisition of a European cardiology business supports global expansion, offering high-margin products, regulatory approvals, and significant synergy potential. Integration will consolidate operations, improve efficiency, and enable faster product launches in regulated markets.
Poly Medicure Press release: M&A Announcement
Poly Medicure issued a press release on September 4, 2025, disclosing material business information to investors.
Poly Medicure Slides: M&A Announcement
Poly Medicure has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2025.
Poly Medicure cuts FY26 export growth guidance to 5-10% from 15-18% earlier
Poly Medicure, a leading player in the medical devices sector, has recently updated its export growth forecast for the financial year 2025-26. The company has trimmed its earlier export growth guidanc...
Poly Medicure Transcript: Q1 25/26
Q1 FY26 saw 5% revenue growth, strong gross margins, and robust domestic expansion, while international business faced headwinds from tariffs and European market disruptions. Guidance for domestic growth remains at 30%, with international revised to 5%-10% and EBITDA margin at 25%-27%.
Poly Medicure Quarterly report: Q1 2026
Poly Medicure has published its Q1 2026 quarterly earnings report on August 8, 2025.
Poly Medicure Slides: Q1 2026
Poly Medicure has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 8, 2025.
Poly Medicure Q1 Results: Revenue jumps 4.8% YoY to 403.21 crore, net profit up 25.8% YoY
Poly Medicure Limited posted steady growth in its consolidated earnings for the quarter ended June 30, 2025. Revenue from operations rose to ₹403.21 crore in Q1 FY26, a 4.8% increase from ₹384.78 cror...